简介
Richard Pestell, AO., MBBS, MD, PhD, MBA, FRACP, FACP, FRCP (Ireland), FRCP (London), MAE., is a clinician scientist who currently serves as the President of the Pennsylvania Cancer and Regenerative Medicine Center and Member of Wistar Institute Cancer Center (Associate) in Philadelphia, USA. He was previously Executive Vice President of Thomas Jefferson University, Philadelphia, USA (30,000 employees, $5.6B USD annual budget).
He has received awards for his research, clinical care and impact on improving health care access including RD Wright Medallion, The Eric Susman Prize in Medicine, Doctor of Medical Sciences, Honoris Causa, University of Melbourne, Doctor Honoris Causa, University of Western Australia. He is an elected member of the European (MAE) and Hungarian Academies of Science. He was appointment as an Officer of the Order of Australia in 2019 by Queen's Elizabeth II for “distinguished service to medicine, and to medical education, as a researcher and physician in the fields of endocrinology and oncology”. https://en.wikipedia.org/wiki/Richard_Pestell
He led cancer not-for-profits, directed two USA Cancer Centers (Lombardi Comprehensive Cancer Center and the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2002-2015). He founded departments, institutes and 5 companies. While Director of the Sidney Kimmel Cancer Center and head of the Jefferson Oncology Service line, the Oncology US News Rankings improved from #64 to #17. He is the past President of INCTR (USA), a global not-for-profit working to impact cancer in the developing world, and was the founding Director of the Delaware Valley Institute for Clinical and Translational Science (University of Delaware, Thomas Jefferson University, Nemours, and Christiana)
His education was in medicine, cancer research, and business. He received his M.D. and Ph.D. degrees from Melbourne University and his MBA from NYU, Stern School of Business. Dr. Pestell completed his M.B. and BS at the University of Western Australia and conducted clinical training in Internal Medicine, Oncology, and Endocrinology. He was the Winthrop Fellow at Harvard Medical School and was a Clinical Fellow at Massachusetts General Hospital.
He has been the Principal Investigator of ~USD $86MM in grants primarily from the NIH, raised ~ USD $50MM from investors for biotechnology company development, published more than 700 works with >106,000 citations, H index 161 and is ranked by Google Scholar #1 in the world for his area of science (“cell cycle”). He holds multiple issued patents in cancer diagnostics and treatment. Of 484 published 1996-2023 publications, 161 have been cited in 677 patents (SciVal). https://en.wikipedia.org/wiki/Richard_Pestell.
He previously and or currently served as a member of the Editorial Board of 14 journals, a Reviewer of 18 funding agencies in 9 countries, NCI Cancer Centers, and European Federal government.
His preclinical studies of cyclin D1 in breast cancer were cited as the basis for the clinical trials of CDK inhibitors, now approved by the FDA for treatment of cancer. His preclinical studies of CCR5 inhibitors are cited as the basis for the current clinical trials of CCR5 inhibitors for cancer.
